

---

# Structural basis of pH-dependent activation in a CLC transporter

---

In the format provided by the authors and unedited

---

**Supplementary Information for**  
**Structural basis of pH-dependent activation in a CLC transporter**


Eva Fortea<sup>#</sup>, Sangyun Lee<sup>#</sup>, Rahul Chadda, Yiorgos Argyros, Priyanka Sandal, Robyn Mahoney-Kruszka, Didar Ciftici, Maria E. Falzone, Gerard Huysmans, Janice L. Robertson, Olga Boudker\* and Alessio Accardi\*

\* Correspondence to:


Alessio Accardi: [ala2022@med.cornell.edu](mailto:ala2022@med.cornell.edu)

Olga Boudker: [olb2003@med.cornell.edu](mailto:olb2003@med.cornell.edu)

# These authors contributed equally to the work



**Supplementary Figure 1: CLC structural organization.** (A) CLC-ec1 transmembrane topology. The residue numbers are shown at the N and C termini of helices A-R. (B) Side view of the structure of CLC-ec1 dimer (PDB: 1OTS). The cartoon representation of each protomer is colored in light gray and green. The sidechain of important residues (S107, E148, E203, and Y445) are shown in stick models and colored yellow in protomer A. The region where the  $\text{Cl}^-$  and  $\text{H}^+$  pathways cross is highlighted by a dashed pink box. (C) Close-up view of the highlighted region. The side chains of residues lining the  $\text{Cl}^-$  pore (delineated by a blue arrow) and the  $\text{H}^+$  pathway (delineated by a red arrow) are shown as sticks. S107 and Y445 delimit the intracellular constriction, and E148 occludes the extracellular constriction in the  $\text{Cl}^-$  pore. E202 and E203 define the intracellular vestibule of the  $\text{H}^+$  pathway. Also shown but not labeled are the following residues lining the  $\text{H}^+$  pathway: E113, A182, L186, A189, F190, F199, M204, F357, I402, and T407. (D) Locations of mutations causing dominant myotonia congenita<sup>1-4</sup> are mapped onto the protomer A of CLC-1 (PDB: 6QVC)<sup>5</sup>. (E) Mutations causing dominant osteopetrosis<sup>6</sup> are mapped onto protomer A of CLC-7 (PDB: 7JMJ)<sup>7</sup>. Mutations within 12 Å of the sister protomer are shown as red spheres (21 out of 38 for CLC-1 and 21 out of 35 for CLC-7), and mutations further away are shown as light blue spheres.



**Supplementary Figure 2. Transmembrane-cytosolic interface in CLC channels and transporters. (A-C)** The transmembrane (TM) domain of CLC-ec1 in Swap (**A**), Turn (**B**), CLC-7 (PDB:7JM7) (**C**) is viewed from the intracellular side. The TM domain is shown in gray surface and cartoon, the cytosolic domain is not shown. For CLC-ec1, the cytosolic domain is the N-terminal  $\alpha A$  helix. In all panels, the interface between the TM and cytosolic domains is colored in red. A residue is defined as part of the interface when its  $Ca-Ca$  distance from any residues in the cytosolic domain is  $< 8 \text{ \AA}$ . E203 of CLC-ec1 and E314 of CLC-7, which indicate the entrance of the intracellular vestibule of the  $H^+$  pathway, are shown as green spheres.

System	CLC-ec1	pH	Initial Velocity ( $\mu\text{M Cl}^- \text{ s}^{-1} \pm \text{SD}$ )	n
1	CLC-ec1	4.5	$4.52 \pm 0.24$	9
2	CLC-ec1*	4.5	$4.22 \pm 0.11$	9
	CLC-ec1	7.5	$0.24 \pm 0.09$	5
3	L25C/A450C	4.5	$1.13 \pm 0.06$	9
4	L25C/A450C*	4.5	$2.44 \pm 0.09$	9
5	L25C	4.5	$3.37 \pm 0.20$	9
6	L25C*	4.5	$3.62 \pm 0.22$	9
7	A450C	4.5	$3.43 \pm 0.14$	9
8	A450C*	4.5	$3.52 \pm 0.15$	9
9	R230C/L249C <sup>^</sup>	4.5	$3.55 \pm 0.23$	3
10	R230C/L249C* <sup>^</sup>	4.5	$3.51 \pm 0.33$	2
11	L25C/A450C/ R230C/L249C	4.5	$1.30 \pm 0.12$	9
12	L25C/A450C/ R230C/L249C*	4.5	$2.79 \pm 0.13$	9
13	E385C <sup>^</sup>	4.5	$2.95 \pm 0.85$	6
14	Q24C	4.5	$2.14 \pm 0.54$	10
15	Q24C-labelled	4.5	$3.84 \pm 0.09$	9
16	Q24C	7.5	$0.24 \pm 0.08$	9
17	Q24C E202Q	4.5	$0.47 \pm 0.12$	9
18	Q24C E202Q	7.5	$0.14 \pm 0.05$	11
19	Q24C E202Y <sup>^</sup>	4.5	$0.13 \pm 0.05$	5
20	Q24C I201W	4.5	$0.78 \pm 0.22$	9
21	Q24C I201W	7.5	$0.17 \pm 0.07$	10

**Supplementary Table 1: Cl<sup>-</sup> transport rates of CLC-ec1 constructs.** Initial velocity of Cl<sup>-</sup> efflux from proteoliposomes reconstituted with WT or mutant CLC-ec1 reconstituted at 0.2  $\mu\text{g}$  protein/mg of lipid. Initial velocity was measured with a linear fit of the initial portion of the flux time course and is reported in  $\mu\text{M Cl}^- \text{ s}^{-1} \pm \text{SD}$  of 5+ independent experiments from 3 independent reconstitutions unless otherwise stated. \* denotes liposomes treated with 30 mM TCEP for 1 hr after extrusion prior to functional measurements. <sup>^</sup> denotes previously characterized CLC-ec1 mutations and therefore these constructs were tested in N=1 (R230C/L249C)<sup>8</sup> or N=2 (E385C)<sup>9</sup> independent preparations. Q24C-labelled was generated by incubating Q24C with maleimide activated LD555p and LD650 fluorophores in the same molar ratio used in smFRET TIRF imaging (CLC-ec1:LD555p:LD650 = 1:2:2.5). The labelled E385C mutant was shown to be as active as the unlabeled form in previous work<sup>10</sup>.

	pH	Cl <sup>-</sup> (mM)	E385C					Q24C				
			Full interface		Reduced interface		N	Helix A bound		Helix A loose		N
			(mean ± SD)	%	(mean ± SD)	%		(mean ± SD)	%	(mean ± SD)	%	
<b>WT</b>	7.5	0	0.83 ± 0.06	100	-	-	754	0.85 ± 0.08	62	0.46 ± 0.09	38	962
<b>WT</b>	7.5	100	0.84 ± 0.06	90	0.42 ± 0.10	10	1167	0.85 ± 0.07	67	0.46 ± 0.07	33	1145
<b>WT</b>	4.5	0	0.80 ± 0.06	88	0.57 ± 0.15	12	924	0.72 ± 0.10	16	0.56 ± 0.07	84	1238
<b>WT</b>	4.5	100	0.79 ± 0.06	64	0.44 ± 0.18	36	1113	0.78 ± 0.07	26	0.54 ± 0.08	74	1719
<b>E202Q</b>	7.5	100	0.84 ± 0.07	100	-	-	1003	0.77 ± 0.06	12	0.46 ± 0.08	88	753
<b>E202Q</b>	4.5	100	0.78 ± 0.07	45	0.26 ± 0.10 0.53 ± 0.10	55	942	0.77 ± 0.10	17	0.56 ± 0.10	83	975
<b>E202Y</b>	7.5	100	0.82 ± 0.07	100	-	-	1172	-	-	0.46 ± 0.08	100	1145
<b>E202Y</b>	4.5	100	0.78 ± 0.08	100	-	-	848	-	-	0.54 ± 0.09	100	920
<b>I201W</b>	7.5	100	0.79 ± 0.08	88	0.45 ± 0.20	12	871	0.85 ± 0.06	100	-	-	1099
<b>I201W</b>	4.5	100	0.76 ± 0.07	40	0.41 ± 0.18	60	696	0.80 ± 0.40	20	0.66 ± 0.13 0.20 ± 0.07	80	1201

**Supplementary Table 2: smFRET summary table.** Populations obtained from Gaussian fitting of time averaged distributions at pH 4.5 or 7.5 in the presence or absence of chloride. Data shown is the mean ± SD of 3+ independent reconstitutions. N is the total number of molecules.

System Number	Starting conformation	Protonation of E202	Cut-off pKa	Cl <sup>-</sup> in Scen
1	Swap	E202(0)	pH 4.5	Yes
2	Swap	E202(0)	pH 7.5	Yes
3	Turn	E202(0)	pH 4.5	Yes
4	Twist	E202(0)	pH 4.5	Yes
5	Bot-Inter	E202(0)	pH 4.5	Yes
6	E202Y	N/A	pH 4.5	Yes
7	Swap	E202(0)	pH 4.5	No
8	Swap	E202(-)*	pH 4.5	No

**Supplementary Table 3: Systems used for free MD simulations.** List of protonation states and Cl<sup>-</sup> occupancy of the central binding site. E202(0) and E202(-) denote a protonated and deprotonated E202 side chain, respectively. \* denotes that E202 was set to be deprotonated at pH 4.5 where it would normally be protonated. The protonation state of other residues was determined using cut-off pKa value of 4.5 and 7.5 to mimic experimental conditions (see Methods and Fig. 4 Supp. 1A). Ten independent replicas of 1  $\mu$ s long trajectory (10  $\mu$ s in total) were generated for each system.

CLC-ec1	hCLC-1	hCLC-3	hCLC-4	hCLC-5	hCLC-7
I201	I290M <sup>11,12</sup>		L279V <sup>13</sup>		
E202	E291K <sup>14</sup>		E280D <sup>13</sup>	E337(E267)A <sup>15</sup> , K <sup>16</sup> , V <sup>17</sup> , or del <sup>18</sup>	E313 (E289)K <sup>19,20</sup>
I422	I556N <sup>21</sup>	I607T <sup>22</sup>	I549T <sup>13</sup>		

**Supplementary Table 4. Disease-causing mutations in human CLCs at positions corresponding to I201, E202, and I422 in CLC-ec1.** The numbers in the parenthesis denote the amino acid sequence number from different isoforms. “del” denotes a deletion mutant.

System No.	Initial position of $\alpha A$	Protonation of E202	Cut-off pKa
12, forward	Bound	E202(0)	pH 4.5
12, reverse	Loose	E202(0)	pH 4.5
13, forward	Bound	E202(0)	pH 7.5
13, reverse	Loose	E202(0)	pH 7.5
14, forward	Bound	E202(-)	pH 4.5
14, reverse	Loose	E202(-)	pH 4.5
15, forward	Bound	E202(-)	pH 7.5
15, reverse	Loose	E202(-)	pH 7.5

**Supplementary Table 5: Molecular systems used for PMF calculations.** The starting conformation of the TM region of CLC-ec1 was the Swap cryoEM conformation determined at pH 4.5 and 100 mM Cl<sup>-</sup>.  $\alpha A$  bound indicates a conformation where it interacts with  $\alpha R$  of the opposite subunit.  $\alpha A$  loose refers to a conformation where it rotates away from the transmembrane region of the exchanger and is ~ parallel to the plane of the membrane, as seen in Turn and Twist cryoEM conformations as well as in free MD simulations. In all cases no Cl<sup>-</sup> was placed in  $S_{cen}$ . E202(0) and E202(-) denote a protonated and deprotonated E202 side chain, respectively. The protonation state of other residues was determined using a cut-off pKa value of 4.5 and 7.5 to mimic experimental conditions (see Methods and Fig. 4 Supp. 1A). Each calculation was performed using 105 windows of 30 ns each for sampling.

<b>CLC-7<sup>PM</sup></b>	<b>Current density at +80 mV (pA/pF) ± SEM</b>	<b>τ at +80 mV (ms) ± SEM</b>	<b>n</b>
<b>WT</b>	20.3 ± 3.1	962 ± 69	9
<b>E311Q</b>	15.9 ± 1.8	192 ± 15	9
<b>L310W</b>	45.2 ± 5.8	38 ± 4	9
<b>G578W</b>	27.7 ± 4.3	37 ± 4	10
<b>L310W+G578W</b>	21.4 ± 3.0	36 ± 5	9

**Supplementary Table 6: Electrophysiological characterization of WT and mutant CLC-7<sup>PM</sup> constructs.** Current density and activation time constant,  $\tau$ , at +80 mV of WT and mutant CLC-7<sup>PM</sup> expressed in HEK293 cells were determined using whole cell patch clamp electrophysiology.  $\tau$  was determined from a single exponential fit of the currents. Data is reported as mean ± SEM of n cells from 3+ independent transfections.

<b>Structure</b>	<b>PDB</b>	<b>EMDB</b>
<b>CLC-ec1 pH 7.5 0 mM Cl<sup>-</sup> Swap</b>	7RNX	EMD-24582
<b>CLC-ec1pH 7.5 100 mM Cl<sup>-</sup> Swap</b>	7RO0	EMD-24584
<b>CLC-ec1pH 4.5 0 mM Cl<sup>-</sup> Swap</b>	7RP6	EMD-24668
<b>CLC-ec1pH 4.5 0 mM Cl<sup>-</sup> Turn</b>	7RSB	EMD-24583
<b>CLC-ec1pH 4.5 100 mM Cl<sup>-</sup> Swap</b>	7N8P	EMD-24241
<b>CLC-ec1pH 4.5 100 mM Cl<sup>-</sup> Turn</b>	7RP5	EMD-24612
<b>CLC-ec1pH 4.5 100 mM Cl<sup>-</sup> Twist</b>	7N0W	EMD-24263
<b>R230C/L249C pH 4.5 100mM Cl<sup>-</sup> Swap</b>	8GA1	EMD-29884
<b>R230C/L249C pH 4.5 100mM Cl<sup>-</sup> Turn</b>	8GA3	EMD-29885
<b>L25C/A450C pH 4.5 100mM Cl<sup>-</sup> Intermediate</b>	8GA5	EMD-29890
<b>L25C/A450C pH 4.5 100mM Cl<sup>-</sup> Twist</b>	8GAH	EMD-29899
<b>E202Y pH 4.5 100mM Cl<sup>-</sup></b>	8GA0	EMD-29883

**Supplementary Table 7: Accession Codes**

<b>Structure</b>	<b>PDB</b>	<b>EMDB</b>
<b>CLC-ec1 pH 7.5 0 mM Cl<sup>-</sup> Swap</b>	7RNX	EMD-24582
<b>CLC-ec1pH 7.5 100 mM Cl<sup>-</sup> Swap</b>	7RO0	EMD-24584
<b>CLC-ec1pH 4.5 0 mM Cl<sup>-</sup> Swap</b>	7RP6	EMD-24668
<b>CLC-ec1pH 4.5 0 mM Cl<sup>-</sup> Turn</b>	7RSB	EMD-24583
<b>CLC-ec1pH 4.5 100 mM Cl<sup>-</sup> Swap</b>	7N8P	EMD-24241
<b>CLC-ec1pH 4.5 100 mM Cl<sup>-</sup> Turn</b>	7RP5	EMD-24612
<b>CLC-ec1pH 4.5 100 mM Cl<sup>-</sup> Twist</b>	7N9W	EMD-24263
<b>R230C/L249C pH 4.5 100mM Cl<sup>-</sup> Swap</b>	8GA1	EMD-29884
<b>R230C/L249C pH 4.5 100mM Cl<sup>-</sup> Turn</b>	8GA3	EMD-29885
<b>L25C/A450C pH 4.5 100mM Cl<sup>-</sup> Intermediate</b>	8GA5	EMD-29890
<b>L25C/A450C pH 4.5 100mM Cl<sup>-</sup> Twist</b>	8GAH	EMD-29899
<b>E202Y pH 4.5 100mM Cl<sup>-</sup></b>	8GA0	EMD-29883

**Supplementary Table 7: Accession Codes**

## References

- 1 Suetterlin, K. *et al.* Translating genetic and functional data into clinical practice: a series of 223 families with myotonia. *Brain : a journal of neurology* **145**, 607-620 (2022). <https://doi.org/10.1093/brain/awab344>
- 2 Pusch, M. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. *Hum. Mutat.* **19**, 423-434 (2002).
- 3 Dupré, N. *et al.* Clinical, electrophysiologic, and genetic study of non-dystrophic myotonia in French-Canadians. *Neuromuscular disorders : NMD* **19**, 330-334 (2009). <https://doi.org/10.1016/j.nmd.2008.01.007>
- 4 Altamura, C. *et al.* The analysis of myotonia congenita mutations discloses functional clusters of amino acids within the CBS2 domain and the C-terminal peptide of the CLC-1 channel. *Hum Mutat* **39**, 1273-1283 (2018). <https://doi.org/10.1002/humu.23581>
- 5 Wang, K. *et al.* Structure of the human CLC-1 chloride channel. *PLOS Biology* **17**, e3000218 (2019). <https://doi.org/10.1371/journal.pbio.3000218>
- 6 Zifarelli, G. The Role of the Lysosomal Cl(-)/H(+) Antiporter CLC-7 in Osteopetrosis and Neurodegeneration. *Cells* **11** (2022). <https://doi.org/10.3390/cells11030366>
- 7 Schrecker, M., Korobenko, J. & Hite, R. K. Cryo-EM structure of the lysosomal chloride-proton exchanger CLC-7 in complex with OSTM1. *eLife* **9**, e59555 (2020). <https://doi.org/10.7554/eLife.59555>
- 8 Nguitrage, W. & Miller, C. CLC Cl<sup>-</sup>/H<sup>+</sup> transporters constrained by covalent cross-linking. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 20659-20665 (2007).
- 9 Khantwal, C. M. *et al.* Revealing an outward-facing open conformational state in a CLC Cl(-)/H(+) exchange transporter. *Elife* **5** (2016). <https://doi.org/10.7554/eLife.11189>
- 10 Chavan, T. S. *et al.* A CLC-ec1 mutant reveals global conformational change and suggests a unifying mechanism for the CLC Cl<sup>-</sup>/H<sup>+</sup> transport cycle. *eLife* **9**, e53479 (2020). <https://doi.org/10.7554/eLife.53479>
- 11 Koty, P. P., Pegoraro, E. & Hoffman, E. P. Linkage and mutation analysis of Thomsen and Becker myotonia families. *American Journal of Human Genetics* **55**, Medium: X; Size: pp. A227.1323 (1994).
- 12 Lehmann-Horn, F., Mailänder, V., Heine, R. & George, A. L. Myotonia levior is a chloride channel disorder. *Human Molecular Genetics* **4**, 1397-1402 (1995). <https://doi.org/10.1093/hmg/4.8.1397>
- 13 Palmer, E. E. *et al.* Functional and clinical studies reveal pathophysiological complexity of CLCN4-related neurodevelopmental condition. *Molecular Psychiatry* **28**, 668-697 (2023). <https://doi.org/10.1038/s41380-022-01852-9>
- 14 Meyer-Kleine, C., Steinmeyer, K., Ricker, K., Jentsch, T. J. & Koch, M. C. Spectrum of mutations in the major human skeletal muscle chloride channel gene (CLCN1) leading to myotonia. *Am J Hum Genet* **57**, 1325-1334 (1995).
- 15 Hoopes, R. R., Jr. *et al.* Evidence for genetic heterogeneity in Dent's disease. *Kidney Int* **65**, 1615-1620 (2004). <https://doi.org/10.1111/j.1523-1755.2004.00571.x>
- 16 Halbritter, J. *et al.* Fourteen Monogenic Genes Account for 15% of Nephrolithiasis/Nephrocalcinosis. *Journal of the American Society of Nephrology* **26**, 543-551 (2015). <https://doi.org/10.1681/asn.2014040388>
- 17 Minamikawa, S. *et al.* Development of ultra-deep targeted RNA sequencing for analyzing X-chromosome inactivation in female Dent disease. *Journal of Human Genetics* **63**, 589-595 (2018). <https://doi.org/10.1038/s10038-018-0415-1>

- 18 Tosetto, E. *et al.* Phenotypic and genetic heterogeneity in Dent's disease--the results of an Italian collaborative study. *Nephrol Dial Transplant* **21**, 2452-2463 (2006). <https://doi.org/10.1093/ndt/gfl274>
- 19 Wang, C. *et al.* The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families. *Journal of bone and mineral metabolism* **30**, 338-348 (2012). <https://doi.org/10.1007/s00774-011-0319-z>
- 20 Li, L., Lv, S.-S., Wang, C., Yue, H. & Zhang, Z.-L. Novel CLCN7 mutations cause autosomal dominant osteopetrosis type II and intermediate autosomal recessive osteopetrosis. *Mol Med Rep* **19**, 5030-5038 (2019). <https://doi.org/10.3892/mmr.2019.10123>
- 21 Plassart-Schiess, E. *et al.* Novel muscle chloride channel (CLCN1) mutations in myotonia congenita with various modes of inheritance including incomplete dominance and penetrance. *Neurology* **50**, 1176-1179 (1998).
- 22 Duncan, A. R. *et al.* Unique variants in CLCN3, encoding an endosomal anion/proton exchanger, underlie a spectrum of neurodevelopmental disorders. *The American Journal of Human Genetics* **108**, 1450-1465 (2021). <https://doi.org/https://doi.org/10.1016/j.ajhg.2021.06.003>